Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, July 20, 2023
Information
Tags: 
Health, FDA, Research, Pharmaceutical, Science, Biotechnology, Webcast, U.S.–Canada Team Tournament (Go), Merrell Dow Pharmaceuticals Inc. v. Thompson, Aurinia
Geotags: 
ALBERTA, NORTH AMERICA, CANADA
⚠ partially generated by AI ↴
Organisation: 
AURINIA PHARMACEUTICALS, AURINIA PHARMACEUTICALS INC., AURINIA
Stock Symbol: 
NASDAQ:AUPH
Summary
Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open.
  • Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.
  • The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com .
  • A replay of the webcast will be available on Aurinia’s website.


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (888) 645-4404 / (862) 298-0702 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Edmonton, Alberta, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

Copyright: 
Copyright Business Wire 2023